Ownership Capital B.V. Trims Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Ownership Capital B.V. reduced its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 17.6% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 270,202 shares of the medical research company’s stock after selling 57,765 shares during the period. Thermo Fisher Scientific comprises approximately 5.3% of Ownership Capital B.V.’s portfolio, making the stock its 7th biggest holding. Ownership Capital B.V.’s holdings in Thermo Fisher Scientific were worth $167,139,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in TMO. Eagle Bluffs Wealth Management LLC increased its position in shares of Thermo Fisher Scientific by 0.6% during the 3rd quarter. Eagle Bluffs Wealth Management LLC now owns 3,714 shares of the medical research company’s stock valued at $2,299,000 after purchasing an additional 23 shares during the last quarter. XML Financial LLC increased its position in Thermo Fisher Scientific by 26.8% during the third quarter. XML Financial LLC now owns 577 shares of the medical research company’s stock valued at $357,000 after acquiring an additional 122 shares during the last quarter. Atria Investments Inc raised its stake in shares of Thermo Fisher Scientific by 5.2% in the third quarter. Atria Investments Inc now owns 49,238 shares of the medical research company’s stock valued at $30,457,000 after acquiring an additional 2,433 shares during the period. Essex Savings Bank boosted its stake in shares of Thermo Fisher Scientific by 10.5% during the 3rd quarter. Essex Savings Bank now owns 1,703 shares of the medical research company’s stock worth $1,053,000 after purchasing an additional 162 shares during the period. Finally, Klingman & Associates LLC raised its position in Thermo Fisher Scientific by 300.1% in the 3rd quarter. Klingman & Associates LLC now owns 3,137 shares of the medical research company’s stock worth $1,940,000 after purchasing an additional 2,353 shares during the period. 89.23% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

TMO has been the topic of a number of analyst reports. Raymond James upped their target price on Thermo Fisher Scientific from $650.00 to $660.00 and gave the company an “outperform” rating in a research note on Thursday, July 25th. Sanford C. Bernstein reduced their target price on Thermo Fisher Scientific from $625.00 to $620.00 and set a “market perform” rating on the stock in a research note on Thursday, October 24th. Stifel Nicolaus lowered their target price on shares of Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating for the company in a research note on Thursday, October 24th. Royal Bank of Canada decreased their price objective on shares of Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Finally, UBS Group upgraded shares of Thermo Fisher Scientific to a “strong-buy” rating in a research note on Monday, September 16th. Four analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus price target of $649.33.

Thermo Fisher Scientific Price Performance

TMO opened at $551.74 on Friday. The firm has a market capitalization of $211.04 billion, a PE ratio of 34.59, a price-to-earnings-growth ratio of 3.65 and a beta of 0.79. The business’s 50-day moving average is $593.95 and its two-hundred day moving average is $583.63. Thermo Fisher Scientific Inc. has a 1 year low of $437.26 and a 1 year high of $627.88. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.63 and a quick ratio of 1.26.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, topping the consensus estimate of $5.25 by $0.03. The firm had revenue of $10.60 billion during the quarter, compared to analyst estimates of $10.63 billion. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. Thermo Fisher Scientific’s revenue was up .2% on a year-over-year basis. During the same quarter in the previous year, the business posted $5.69 EPS. Research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.69 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Friday, December 13th will be paid a dividend of $0.39 per share. The ex-dividend date is Friday, December 13th. This represents a $1.56 annualized dividend and a yield of 0.28%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 9.78%.

Insider Activity at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $554.29, for a total value of $5,542,900.00. Following the completion of the transaction, the chief executive officer now directly owns 121,192 shares of the company’s stock, valued at $67,175,513.68. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Monday, October 28th. The stock was sold at an average price of $554.29, for a total value of $5,542,900.00. Following the completion of the transaction, the chief executive officer now owns 121,192 shares in the company, valued at $67,175,513.68. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $560.16, for a total value of $168,048.00. Following the sale, the executive vice president now owns 16,663 shares in the company, valued at approximately $9,333,946.08. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 28,150 shares of company stock valued at $15,676,125 in the last ninety days. Corporate insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.